4565 Stock Overview
Develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Nxera Pharma Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥1,141.00 |
| 52 Week High | JP¥1,826.00 |
| 52 Week Low | JP¥1,100.00 |
| Beta | 0.63 |
| 11 Month Change | -5.70% |
| 3 Month Change | -18.50% |
| 1 Year Change | -17.85% |
| 33 Year Change | -42.66% |
| 5 Year Change | -48.93% |
| Change since IPO | -43.93% |
Recent News & Updates
Recent updates
Nxera Pharma Co., Ltd. (TSE:4565) Stocks Pounded By 25% But Not Lagging Industry On Growth Or Pricing
Sep 25
Nxera Pharma Co., Ltd.'s (TSE:4565) P/S Still Appears To Be Reasonable
Jun 26Is Nxera Pharma (TSE:4565) A Risky Investment?
Apr 06Sosei Group Corporation (TSE:4565) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable
Mar 08Shareholder Returns
| 4565 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | 0.4% | 0.7% | -1.1% |
| 1Y | -17.9% | 10.1% | 10.7% |
Return vs Industry: 4565 underperformed the JP Pharmaceuticals industry which returned 10.1% over the past year.
Return vs Market: 4565 underperformed the JP Market which returned 10.7% over the past year.
Price Volatility
| 4565 volatility | |
|---|---|
| 4565 Average Weekly Movement | 6.6% |
| Pharmaceuticals Industry Average Movement | 3.6% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in JP Market | 7.5% |
| 10% least volatile stocks in JP Market | 2.1% |
Stable Share Price: 4565's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4565's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 372 | Chris Cargill | www.nxera.life |
Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company’s development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders.
Nxera Pharma Co., Ltd. Fundamentals Summary
| 4565 fundamental statistics | |
|---|---|
| Market cap | JP¥102.13b |
| Earnings (TTM) | -JP¥3.71b |
| Revenue (TTM) | JP¥29.28b |
3.5x
P/S Ratio-27.6x
P/E RatioIs 4565 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4565 income statement (TTM) | |
|---|---|
| Revenue | JP¥29.28b |
| Cost of Revenue | JP¥5.43b |
| Gross Profit | JP¥23.85b |
| Other Expenses | JP¥27.56b |
| Earnings | -JP¥3.71b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -41.28 |
| Gross Margin | 81.46% |
| Net Profit Margin | -12.68% |
| Debt/Equity Ratio | 95.8% |
How did 4565 perform over the long term?
See historical performance and comparison